Navigation Links
Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
Date:3/17/2010

CARLSBAD, Calif., March 17 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Barclays' 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at 3:45 p.m. ET at Loews Miami Hotel.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.isispharm.com

'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)...  While you may be familiar with watching a film or TV show in high definition, ... 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the medical industry,s ... - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... Mich. , May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... company released a video of two patients who tell their personal story and encourage those ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... Pastor and Overseer at The House of Yahweh, has written a new article this week ... helping to stop cancer. Yisrayl says there are too many suffering and dying from the ... industries will pay close attention and take action. The Pastor says that the root cause ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, DSc, RN, FACHE, ... of the South announced today that Dr. Robert Menuet, Interventional Cardiologist with Cardiovascular ... Ultrasound Guided Coronary Atherectomy. , This procedure involves the removal of ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
(Date:5/5/2016)... Illinois (PRWEB) , ... May 05, 2016 , ... ... its “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit their ... a “tobacco product,” apply to all vaping products that entered the market since ...
(Date:5/5/2016)... Francisco, CA (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May ... will take on steep California terrain at the first Team Semper Fi Mountain Bike Camp, ... Joining them will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro ...
Breaking Medicine News(10 mins):